MedTrace Logo

Evaluation of the Efficiency of Neutrophil-Lymphocyte Ratio in Predicting Delirium in Geriatric Patients Undergoing Hip Fracture Surgery

NCT07741175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-08-03

No results posted yet for this study

Summary

Aim:

Postoperative delirium (POD) is one of the most common complications in elderly patients and is associated with increased morbidity, mortality, length of hospital stay and medical care costs. One of the mechanisms proposed for the pathophysiology of delirium is neuroinflammatory processes. The neutrophil-lymphocyte ratio (NLR) is a cost-effective and easily applicable marker of inflammation and oxidative stress. NLR has been used to predict complications, determine prognosis and evaluate mortality in various patient groups and diseases. Most of the studies investigating the relationship between NLR and postoperative delirium in the elderly patient group undergoing hip fracture surgery are retrospective, and the number of prospective studies with large case-series is insufficient. In this study, the investigators aimed to evaluate the effectiveness of NLR in predicting postoperative delirium in elderly patients undergoing hip fracture surgery.

Conditions

  • Delirium
  • Elderly Patient
  • Hip Fracture Surgery
  • Neutrophil Lymphocyte Ratio

Sponsors & Collaborators

  • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

    lead OTHER

Principal Investigators

  • Dilek Kalayci · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2022-10-27
Completion
2022-10-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07741175 on ClinicalTrials.gov